SARASOTA, Fla., June 25, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal…
The pooled analysis included data from 4 international clinical trials spanning an array of hard-to-treat indications including skin, head &…
MALVERN, Pa., June 25, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”),…
Statistically significant, potent, and durable allele-selective silencing: 46% mean reduction in CSF mutant huntingtin (mHTT) protein compared to placebo, preservation…
BETHESDA, Md., June 25, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology…
Becomes the world's first and only clinically approved nicotine inhaler enabling rapid absorption via the lungs to help smokers replace,…
Company Announcement, Helsinki, 25 June 2024 at 9:30 AM (EEST) Insider Information: Nexstim Plc’s offering for an EUR 750,000 convertible…
Company Announcement, Helsinki, 25 June 2024 at 9 AM (EEST) Insider Information: Nexstim Plc launches an unsecured convertible bond offering…
OCREVUS subcutaneous (SC) injection offers a new, 10-minute administration of OCREVUS with comparable efficacy and safety to intravenous infusion (IV)…
SHELTON, CT / ACCESSWIRE / June 24, 2024 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), a clinical stage global leader…